Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs

 
Rail passengers wearing masks

It’s Freedom Day in the UK—but COVID Is Not Going Away Any Time Soon

The UK government is removing almost all COVID-19 restrictions from England in what the Prime Minister has as “Freedom Day”, but unfettered freedom does not exist. COVID is not going away any time soon. It’s time to prioritize transparency, consultation and long-term solutions. Everyone wants the world to return to normal, but we need to find a new normal that maximizes freedom in a world where COVID will be ever-present, rather than trying to return to a pre-pandemic status quo.

An image of shipping containers.

Shock to the System: Understanding Global Medical Supply, Shortages in COVID-19 Crisis, and How to Prepare for Future Disruptions

Since March of 2020, COVID-19 changed most aspects of life as we knew it, from our personal day-to-day activities to the systems, processes, and structures that keep the global economy interconnected and moving. This included pharmaceutical production and distribution, where anecdotal evidence suggested production problems, export bans, and trade disruption could significantly impact vital medicines access in low- and middle-income countries.

A figure of the summary of costs and consequences to consider in COVID-19 vaccine HTA.

Who Gets a COVID-19 Vaccine and Who Pays? The Need for Economic Analysis

In 2020, epidemiological modelling went from relative obscurity to being central in helping governments, and the public, understand COVID-19 as it spread around the world. In 2021, with the emergence of effective COVID-19 vaccines, Health Technology Assessment (HTA) will be critical to making the best possible decisions in bringing the pandemic under control, particularly in low-and middle-income countries (LMICs). In this blog we look at the potential of HTA to inform how much vaccine countries should buy, who should pay, and how vaccines can be most effectively delivered.

Chart showing steps from early trials to final distribution of a vaccine

Vaccine Preliminary Results: Here Is Why We Need to Exercise Caution

As vaccines complete the different phases of development (pre-clinical, phase I, phase II, phase III, regulatory review, and license), results will be published in the scientific literature and announced to the public through the media and press releases. We our currently working as part of a larger group to interview experts and give better guidance on the timelines and probabilities of success for a vaccine against COVID-19. In the meantime, it is important not to read too much into early stage results—this is why.

Pages